Trials
Search / Trial NCT06442280

SGLT-2 Inhibitor and High-Dose Furosemide Plus Small-Volume Hypertonic Saline Solution in Acute HF

Launched by UNIVERSITY OF PALERMO · Jun 2, 2024

Apply for Trial

Trial Information

Current as of March 12, 2025

Not yet recruiting

Keywords

Acute Heart Failure Diabetes Type 2 Sglt 2 Inhibitors Furosemide Hypertonic Solution

ClinConnect Summary

All enrolled patients will undergo a comprehensive physical examination post-randomization. This examination will involve a meticulous assessment of congestive heart failure (CHF) indicators, encompassing the measurement of bodyweight (BW) (taken in the morning before breakfast), supine and standing blood pressure (BP \[average of 3 readings\]), and heart rate (HR). Fasting blood samples will be collected daily throughout the hospital stay to ascertain serum laboratory parameters (creatinine, sodium, potassium, and N-terminal pro b-type natriuretic peptide) until achieving a clinically stab...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • • acute heart failure;
  • • diabetes type 2.
  • Exclusion Criteria:
  • • low estimated glomerular filtration rate;
  • • hypernatremia;
  • • diabetes type 1;
  • • non-cardiac causes of dyspnea;
  • • cardiogenic shock;
  • • recent occurrence of Acute Coronary Syndrome;
  • • ketoacidosis;
  • • hyperosmolar hyperglycemic syndrome.

Trial Officials

Giuseppe Miceli, PhD

Principal Investigator

A.O.U.P. Paolo Giaccone Palermo

About University Of Palermo

The University of Palermo, a distinguished institution located in Italy, is dedicated to advancing medical research and education through innovative clinical trials. Renowned for its commitment to scientific excellence, the university leverages its multidisciplinary expertise and state-of-the-art facilities to conduct research that addresses critical healthcare challenges. By fostering collaborations with leading researchers and healthcare professionals, the University of Palermo aims to translate scientific findings into effective therapies, ultimately contributing to improved patient outcomes and public health advancements.

Locations

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0